IMR Press / FBL / Volume 24 / Issue 3 / DOI: 10.2741/4734

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Role of microRNAs in the development of hepatocellular carcinoma and acquired drug resistance

Show Less
1 Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, 1801 Fayetteville St. Durham NC 27707, USA
2 Department of Pharmaceutical Sciences, North Carolina Central University, 1801 Fayetteville St. Durham NC 27707, USA

*Author to whom correspondence should be addressed.

Front. Biosci. (Landmark Ed) 2019, 24(3), 545–554;
Published: 1 January 2019

Hepatocellular Carcinoma (HCC) is a leading cause of cancer related death worldwide with a relatively poor survival rate. Aside from liver resection and subsequent transplant, the most effective and leading curative measure for HCC is the chemotherapeutic, sorafenib, a multi-kinase inhibitor used for treatment of late stage HCC. However, the effects of sorafenib are short lived due to the liver’s rapid acquisition of Multi-Drug Resistance (MDR). MicroRNAs (miRNAs) have emerged as critical regulatory molecules for almost every biochemical pathway in an organism. The development and progression of HCC and acquired MDR are critically influenced by miRNAs through regulation of key genes in cell regulatory pathways. This review explores the involvement of miRNAs in development of HCC and their role in key signaling pathways for MDR in HCC.

Hepatocellular Carcinoma
Drug Resistance
Cancer Progression
Cell Survival
Back to top